What’s Inside?

Bringing a bioconjugate or ADC therapy to patients is rarely straightforward. Success depends on coordinating multiple areas of expertise, from biologics, linker and payload chemistry, and conjugation through to analytical testing, manufacturing, formulation, and regulatory support. When those pieces are not aligned, timelines can slip and risks can increase.

To better understand what sponsors need most, Contract Pharma surveyed professionals working across bioconjugate and ADC programs. The report explores where organizations are focusing their development efforts, the challenges they face as programs advance, and the capabilities they look for when selecting a CDMO partner.